These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 21044439)

  • 1. Use of MTX in the elderly and in patients with compromised renal function.
    Morgacheva O; Furst DE
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S85-94. PubMed ID: 21044439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The rational use of methotrexate in rheumatoid arthritis and other rheumatic diseases.
    Furst DE
    Br J Rheumatol; 1997 Nov; 36(11):1196-204. PubMed ID: 9402864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An update on methotrexate.
    Braun J; Rau R
    Curr Opin Rheumatol; 2009 May; 21(3):216-23. PubMed ID: 19373092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of methotrexate in childhood rheumatic diseases.
    Wallace CA
    Arthritis Rheum; 1998 Mar; 41(3):381-91. PubMed ID: 9506564
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of genetic polymorphisms in the folate pathway on methotrexate therapy in rheumatic diseases.
    Stamp LK; Roberts RL
    Pharmacogenomics; 2011 Oct; 12(10):1449-63. PubMed ID: 22008049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology and pharmacokinetics of methotrexate in rheumatic disease. Practical issues in treatment and design.
    Hillson JL; Furst DE
    Rheum Dis Clin North Am; 1997 Nov; 23(4):757-78. PubMed ID: 9361154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Management of antirheumatic drugs in kidney failure].
    Manganelli R; Manganelli S; Iannaccone S; De Simone W
    G Ital Nefrol; 2015; 32(6):. PubMed ID: 26845207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is low-dose methotrexate nephrotoxic? Case report and review of the literature.
    Izzedine H; Launay-Vacher V; Karie S; Caramella C; de Person F; Deray G
    Clin Nephrol; 2005 Oct; 64(4):315-9. PubMed ID: 16240905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of action of methotrexate.
    Chan ES; Cronstein BN
    Bull Hosp Jt Dis (2013); 2013; 71 Suppl 1():S5-8. PubMed ID: 24219035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methotrexate pharmacogenetics in rheumatoid arthritis.
    Brinker RR; Ranganathan P
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S33-9. PubMed ID: 21044431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study.
    Weber-Schoendorfer C; Chambers C; Wacker E; Beghin D; Bernard N; ; Shechtman S; Johnson D; Cuppers-Maarschalkerweerd B; Pistelli A; Clementi M; Winterfeld U; Eleftheriou G; Pupco A; Kao K; Malm H; Elefant E; Koren G; Vial T; Ornoy A; Meister R; Schaefer C
    Arthritis Rheumatol; 2014 May; 66(5):1101-10. PubMed ID: 24470106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse effects of low dose methotrexate in rheumatoid arthritis patients.
    Gilani ST; Khan DA; Khan FA; Ahmed M
    J Coll Physicians Surg Pak; 2012 Feb; 22(2):101-4. PubMed ID: 22313647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis.
    Bathon JM; Fleischmann RM; Van der Heijde D; Tesser JR; Peloso PM; Chon Y; White B
    J Rheumatol; 2006 Feb; 33(2):234-43. PubMed ID: 16465653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacogenetics of methotrexate.
    Hider SL; Bruce IN; Thomson W
    Rheumatology (Oxford); 2007 Oct; 46(10):1520-4. PubMed ID: 17586865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose and high-dose methotrexate are two different drugs in practical terms.
    Malaviya AN; Sharma A; Agarwal D; Kapoor S; Garg S; Sawhney S
    Int J Rheum Dis; 2010 Oct; 13(4):288-93. PubMed ID: 21199463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of methotrexate in children with rheumatic diseases.
    Gutiérrez-Suárez R; Burgos-Vargas R
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S122-7. PubMed ID: 21044445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients.
    Köller MD; Aletaha D; Funovits J; Pangan A; Baker D; Smolen JS
    Rheumatology (Oxford); 2009 Dec; 48(12):1575-80. PubMed ID: 19812228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylenetetrahydrofolate reductase polymorphisms and methotrexate: no association with response to therapy nor with drug-related adverse events in an Italian population of rheumatic patients.
    Taraborelli M; Andreoli L; Archetti S; Ferrari M; Cattaneo R; Tincani A
    Clin Exp Rheumatol; 2009; 27(3):499-502. PubMed ID: 19604445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methotrexate--the anchor drug--an introduction.
    Pincus T; Cronstein B; Braun J
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S1-2. PubMed ID: 21044424
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients.
    Bressolle F; Bologna C; Kinowski JM; Sany J; Combe B
    Ann Rheum Dis; 1998 Feb; 57(2):110-3. PubMed ID: 9613341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.